Last week Venable scored an important victory in federal court on behalf of Ranbaxy in the first test of what limits may be placed on reverse payment deals among drugmakers to protect steady streams of revenue on popular drugs. The case against AstraZeneca and Ranbaxy challenged a 2008 settlement of a patent lawsuit that stalled sales of a cheaper version of Nexium in the U.S. until AstraZeneca's patents expired last May. The case is the first reverse payment antitrust suit to go to trial since the U.S. Supreme Court ruled in June 2013 that the Hatch-Waxman Act settlements could be challenged under federal antitrust law.
The Venable trial team was led by Doug Baldridge and included partners Lisa Jose Fales, Danielle R. Foley, associates Vincent Verrocchio, Paul Feinstein, Sarah Choi and Molly Cusson with Marta Markowska and Jeanne Mooney.
FiercePharma featured news of the victory on December 8, 2014 as did The Pink Sheet on December 5.
Speaking with The Pink Sheet following the verdict, Baldridge said "it is not possible to know if the verdict will have an impact as judges are still weighing how to interpret the Supreme Court’s ruling last year on pay-for-delay cases." He added, "I'm very grateful for the way the jury took their job so seriously, considered all the evidence and got the right result."
The Venable trial team was led by Doug Baldridge and included partners Lisa Jose Fales, Danielle R. Foley, associates Vincent Verrocchio, Paul Feinstein, Sarah Choi and Molly Cusson with Marta Markowska and Jeanne Mooney.
FiercePharma featured news of the victory on December 8, 2014 as did The Pink Sheet on December 5.
Speaking with The Pink Sheet following the verdict, Baldridge said "it is not possible to know if the verdict will have an impact as judges are still weighing how to interpret the Supreme Court’s ruling last year on pay-for-delay cases." He added, "I'm very grateful for the way the jury took their job so seriously, considered all the evidence and got the right result."